Press Release
Category Added in a WPeMatico Campaign
-
Business Wire28 March 2026
Kardigan Announces Positive Phase 2 Data for Tonlamarsen in Patients with Uncontrolled Hypertension Presented as Late-Breaker at ACC.26 and Simultaneously Published in JACC
Patients treated with tonlamarsen experienced statistically significant reductions in plasma angiotensinogen levels and clinically meaningful changes in systolic blood pressure…
Read More » -
Business Wire28 March 2026
Debevoise Secures Second Circuit Affirmance of Dismissal of $16 billion Claim Against YPF S.A.
NEW YORK–(BUSINESS WIRE)–Debevoise & Plimpton LLP has secured affirmance from the U.S. Court of Appeals for the Second Circuit of…
Read More » -
Business Wire28 March 2026
YRD Investors Have Opportunity to Join Yiren Digital Ltd. Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$YRD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire28 March 2026
PODD Investors Have Opportunity to Join Insulet Corporation Fraud Investigation with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PODD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire28 March 2026
PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire28 March 2026
PRTH Investors Have the Opportunity to Join Investigation of Priority Technology Holdings, Inc. with the Schall Law Firm
LOS ANGELES–(BUSINESS WIRE)–$PRTH—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf…
Read More » -
Business Wire28 March 2026
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase…
Read More » -
Business Wire28 March 2026
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase…
Read More » -
Business Wire28 March 2026
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with…
Read More » -
Business Wire28 March 2026
Corcept Presents Data from MOMENTUM Trial at American College of Cardiology Annual Scientific Session
Hypercortisolism identified in 27.3 percent of patients with resistant hypertension REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage…
Read More »